Loading stock data…
AEON
$0.72-0.01 (-1.77%)
Market ClosedLast close Jun 9
AEON Biopharma, Inc., a clinical stage biopharmaceutical company, focuses on developing botulinum toxins.
Historical Price
Price (Candle)
50-Day SMA
200-Day SMA
Whystock Brain
The Narrative
AEON Biopharma, Inc. in the Healthcare sector is trading at $0.72 with a market capitalization of $19M. Wall Street consensus targets $6.70 (2 analysts), implying a +834.8% move over the next 12 months. The stock is currently near its 52-week low of $0.62, remaining 24.6% below its 200-day moving average. On fundamentals, Piotroski 3/9 flags weak fundamentals, Altman Z in the distress zone. Risk note: RSI 23 is oversold, raising the odds of a near-term bounce. The Whystock Score of 35/100 signals elevated caution as multiple indicators diverge.
Ecosystem Influences
Sell-side targets imply +834.8% upside over 12 months
Long-term trend bearish (price vs 200-day SMA)
Oversold momentum (RSI 23) — potential for technical mean-reversion
Loading Financials...
Peer Comparison
JNJUNHPFE
Whystock Valuation Model
Anchored to each ticker's own 5-year median trailing P/E, tilted by current ROE and growth. Fair P/E = own median P/E + (ROE × 10) + (max(revenue growth, earnings growth) × 15), capped at ±30% around the historical anchor. Fair Value = (Current Price ÷ Trailing P/E) × Fair P/E. Premium compounders like COST/MSFT are judged against their own multi-year norm rather than a sector median. Falls back to the sector-anchored formula (Tech ≈ 28, Comm Services ≈ 24, Utilities ≈ 18, Financials ≈ 14, etc.) for recent IPOs and tickers with insufficient history (< 24 monthly samples). Result is a normalised multiple gauge — not a price target.
Current Price$0.72
Potential Downside
0%
Whystock Fair Value$0.72
Price
UndervaluedFair ValueOvervalued
Simplified model based on P/E and ROE. Not a substitute for full valuation analysis. Data may be delayed. See our Terms.
Fundamentals
AEON Biopharma, Inc., a clinical stage biopharmaceutical company, focuses on developing botulinum toxins. It develops ABP-450 (prabotulinumtoxinA) injection for debilitating medical conditions, which completed Phase 2 study for the treatment of cervi...
Market Cap
Total dollar market value of a company's outstanding shares of stock (Price * Shares).
$19.24M
P/E Ratio
Priced for growth. Investors expect sustained double-digit expansion.
-
Beta
High-beta play. Expect amplified moves vs. the broad market.
-
Div Yield
Low to zero yield. Return is entirely dependent on price appreciation.
0.00%
ROE
Elite ROE. Management converts capital into profit efficiently.
358.82%
Volume
Today's trading volume
54,445
Recent News
Why You Might Be Interested In Aeon Co. (M) Bhd. (KLSE:AEON) For Its Upcoming Dividend
Regular readers will know that we love our dividends at Simply Wall St, which is why it's exciting to see Aeon Co. (M...
Aeon Biopharma announces FDA feedback after Type 2a meeting
Aeon Biopharma (AEON) announced feedback from the FDA following a biosimilar biological product development Type 2a meeting. During the meeting, held in January, the FDA reviewed the company’s proposed analytical similarity strategy under the 351(k) biosimilar pathway and provided feedback supporting the company’s planned analytical development approach. The agency acknowledged the scientific challenges associated with characterizing a 900 kDa botulinum neurotoxin complex, provided constructive
An Intrinsic Calculation For Aeon Co. (M) Bhd. (KLSE:AEON) Suggests It's 42% Undervalued
Key Insights Aeon (M) Bhd's estimated fair value is RM1.89 based on 2 Stage Free Cash Flow to Equity Aeon (M) Bhd's...
Investors in Aeon (M) Bhd (KLSE:AEON) have unfortunately lost 24% over the last year
Passive investing in an index fund is a good way to ensure your own returns roughly match the overall market. But if...
The Returns At Aeon (M) Bhd (KLSE:AEON) Aren't Growing
What are the early trends we should look for to identify a stock that could multiply in value over the long term...